pd

Road Development and Poverty Reduction: The Case of Lao PDR

Lack of access to good road networks is a major constraint on the incomes and welfare of the poor. Using household expenditure survey data for Lao PDR this paper models the causes of poverty and shows the impact on poverty levels of road improvements.



  • Publications/Papers and Briefs

pd

IMF seeks update on revenue system’s digital overhaul

• Holds introductory meeting with finance minister
• Govt pledges to end gas supply to captive power plants by Jan
• Lender’s team to hold joint session with power and petroleum divisions today

ISLAMABAD: The International Monetary Fund (IMF) has sought a detailed, output-based update on Pakistan’s digitalisation plans for its revenue system, including the use of artificial intelligence to expand the tax base and increase collections.

On the energy side, the country has pledged to halt gas supply to captive power plants (CPPs) by January 2025, redirecting them to the national grid despite a strong pushback from influential rent-seeking industrialists. The IMF has firmly rejected any amendments to this programme benchmark.

The visiting IMF team, led by Pakistan’s mission chief Nathan Porter, held an introductory meeting on Tuesday with Finance Minister Muhammad Aurangzeb. Minister of State for Revenue Ali Pervez Malik, State Bank Governor Jameel Ahmad and Federal Board of Revenue (FBR) Chairman Rashid Mehmood Langrial were also present.

The mission is also holding separate technical sessions with all the stakeholders, including the FBR, power and petroleum divisions and the energy sector regulatory authorities. In all these engagements, the mission appeared to have not expressed its mind so far, except from raising exploratory questions, participants told Dawn.

It is not yet clear if the dialogue would lead to policy-level discussions that had been a critical part of IMF programmes’ quarterly reviews.

The current $7 billion Extended Fund Facility (EFF), however, has been designed in a manner that the IMF and Pakistan authorities should hold biannual review meetings for the disbursement of about $1bn instalments during each cycle.

The first formal review has to take place based on the end-December performance for Pakistan to qualify for disbursement for a second instalment of over $1bn by March 15, 2025.

Officials said the IMF mission has called for detailed explanations on the digitalisation of FBR’s processes for revenue collection, application of artificial intelligence for identifying and tracing tax evaders and their taxable incomes and businesses and involvement of specialised expert firms. They have also sought a complete update on the track-and-trace system.

In initial meetings, the FBR attributed recent revenue shortfalls — particularly in the first month of the second quarter — to the declining inflation.

The power sector’s performance appears to be within agreed limits concerning circular debt and current revenues.

Circular debt rose by about Rs70bn, below earlier estimates of Rs240-250bn. A circular debt management plan was approved only last week by the Economic Coordination Committee (ECC), led by the finance minister.

Sources said the government had been going back and forth over the disconnection of gas supply to inefficient captive power plants, belonging mostly to the textile sector, to utilise surplus capacity in the national power grid.

The industrialists have, however, now mustered support from gas companies. Some stakeholders are now pushing for the supply of imported LNG to CPPs at a weighted average cost of local and imported molecules on the premise that electricity connections were not available or were insufficient in certain areas.

The IMF mission is scheduled to have a joint session with the power and petroleum divisions on Wednesday (today) to discuss their interrelated issues, including circular debt, planned tariff adjustments, loss reduction programmes and recoveries.

Published in Dawn, November 13th, 2024




pd

4500 printer manual pdf

4500 printer manual pdf




pd

71b manual pdf

71b manual pdf




pd

35s user manual pdf

35s user manual pdf




pd

to write scripts in unix pdf

to write scripts in unix pdf




pd

11c calculator manual pdf

11c calculator manual pdf




pd

6500a plus manual pdf

6500a plus manual pdf




pd

c309a troubleshooting pdf

c309a troubleshooting pdf




pd

to write a yoga proposal pdf

to write a yoga proposal pdf




pd

to write an honors thesis in psychology pdf

to write an honors thesis in psychology pdf




pd

8570w manual pdf

8570w manual pdf




pd

3800 service manual pdf

3800 service manual pdf




pd

to write a resume pdf

to write a resume pdf




pd

5610 manual pdf

5610 manual pdf




pd

48gx manual pdf

48gx manual pdf




pd

alm 11 users guide pdf

alm 11 users guide pdf




pd

40gs manual pdf

40gs manual pdf




pd

c3180 printer troubleshooting pdf

c3180 printer troubleshooting pdf




pd

1000 manual pdf

1000 manual pdf




pd

4700 service manual pdf

4700 service manual pdf




pd

to write a case study in psychology pdf

to write a case study in psychology pdf




pd

12c user manual pdf

12c user manual pdf




pd

48gx user manual pdf

48gx user manual pdf




pd

Update of the Readiness Assessment for Cross-Border Paperless Trade: Bangladesh

This report highlights Bangladesh’s cross-border paperless trade readiness, outlines the significant legal and technical gaps it still needs to address, and provides a comprehensive action plan.




pd

L44429-IND: Climate Adaptation in Vennar Sub Basin in Cauvery Delta (CAVSCD) Project[Infrastructure Improvement and Reconstruction Works on Pandavaiyar river from 109.270 Km to 148.020 Km Package No CAVSCD/TN/ PDR]




pd

Loan No. 2542-BAN (SF): Participatory Small Scale Water Resources Sector Project [LGED/PSSW/PD/Ukhia/Cox/R-4/2013]




pd

The Bond Market in the Republic of Korea: An ASEAN+3 Bond Market Guide Update

This edition of the ASEAN+3 Bond Market Guide series focuses on updates in the Republic of Korea’s (ROK) market since the publication of the previous guide for the ROK in 2018.




pd

Early COPD Treatment Slows Disease

Title: Early COPD Treatment Slows Disease
Category: Health News
Created: 8/28/2009 12:00:00 AM
Last Editorial Review: 8/28/2009 12:00:00 AM




pd

Health Tip: Recognizing COPD

Title: Health Tip: Recognizing COPD
Category: Health News
Created: 8/25/2010 10:10:00 AM
Last Editorial Review: 8/25/2010 12:00:00 AM




pd

Health Tip: Help Keep COPD in Check

Title: Health Tip: Help Keep COPD in Check
Category: Health News
Created: 8/31/2012 8:05:00 AM
Last Editorial Review: 8/31/2012 12:00:00 AM




pd

The Priority Updates from the Research Literature (PURLs) Methodology




pd

The Evolution of Intermittent Mandatory Ventilation: Update and Implications for Home Care




pd

Comparing Highs and Flows in Patients With COPD With Chronic Hypercapnic Respiratory Failure




pd

Home Respiratory Strategies in Patients With COPD With Chronic Hypercapnic Respiratory Failure

BACKGROUND:Home noninvasive ventilation (NIV) may improve chronic hypercarbia in COPD and patient-important outcomes. The efficacy of home high-flow nasal cannula (HFNC) as an alternative is unclear.METHODS:We searched MEDLINE, Embase, Cochrane CENTRAL, Scopus, and ClinicalTrials.gov for randomized trials of subjects from inception to March 31, 2023, and updated the search on July 14, 2023. We performed a frequentist network meta-analysis and assessed the certainty of the evidence using the Grading of Recommendations Assessment, Development, and Evaluation approach. We analyzed randomized controlled trials (RCTs) comparing NIV, HFNC, or standard care in adult subjects with COPD with chronic hypercapnic respiratory failure. Outcomes included mortality, COPD exacerbations, hospitalizations, and quality of life (St George Respiratory Questionnaire [SGRQ]).RESULTS:We analyzed 24 RCTs (1,850 subjects). We found that NIV may reduce the risk of death compared to standard care (relative risk 0.82 [95% CI 0.66–1.00]) and probably reduces exacerbations (relative risk 0.71 [95% CI 0.58–0.87]). HFNC probably reduces exacerbations compared to standard care (relative risk 0.77 [0.68–0.88]), but its effect on mortality is uncertain (relative risk 1.20 [95% CI 0.63–2.28]). HFNC probably improves SGRQ scores (mean difference −7.01 [95% CI −12.27 to −1.77]) and may reduce hospitalizations (relative risk 0.87 [0.69–1.09]) compared to standard care. No significant difference was observed between HFNC and NIV in reducing exacerbations.CONCLUSIONS:Both NIV and HFNC reduce exacerbation risks in subjects with COPD compared to standard care. HFNC may offer advantages in improving quality of life.




pd

The noninvasive ventilation outcomes score in patients requiring NIV for COPD exacerbation without prior evidence of airflow obstruction

Introduction

Exacerbation of COPD complicated by respiratory acidaemia is the commonest indication for noninvasive ventilation (NIV). The NIV outcomes (NIVO) score offers the best estimate of survival for those ventilated. Unfortunately, two-thirds of cases of COPD are unrecognised, and patients may present without COPD having been confirmed by spirometry.

Methods

In the 10-centre NIVO validation study there was no pre-admission spirometry in 111 of 844 consecutive patients (termed "clinical diagnosis" patients). We compared the performance of the NIVO, DECAF and CURB-65 scores for in-hospital mortality in the clinical diagnosis cohort. Usual clinical practice was not influenced, but confirmation of COPD in the year following discharge was captured.

Results

In the clinical diagnosis cohort, in-hospital mortality was 19.8% and rose incrementally across the NIVO risk categories, consistent with the NIVO validation cohort. NIVO showed good discrimination in the clinical diagnosis cohort: area under the receiver operating curve 0.724, versus 0.79 in the NIVO validation cohort. At 1 year after discharge, 41 of 89 clinical diagnosis patients had undertaken diagnostic spirometry; 33 of 41 had confirmation of airflow obstruction (forced expiratory volume in 1 s/(forced) vital capacity <0.7), meaning the diagnosis of COPD was incorrect in 19.5% of cases.

Discussion

These data support the use of the NIVO score in patients with a "clinical diagnosis" of COPD. NIVO can help guide shared decision-making, assess risk-adjusted outcomes by centre and challenge prognostic pessimism. Accurate diagnosis is critical to ensure that acute and long-term treatment is optimised; this study highlights failings in the follow-up of such patients.




pd

The Updated Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT 2.0)

The Registry of Fast Myocardial Perfusion Imaging with Next-Generation SPECT (REFINE SPECT) has been expanded to include more patients and CT attenuation correction imaging. We present the design and initial results from the updated registry. Methods: The updated REFINE SPECT is a multicenter, international registry with clinical data and image files. SPECT images were processed by quantitative software and CT images by deep learning software detecting coronary artery calcium (CAC). Patients were followed for major adverse cardiovascular events (MACEs) (death, myocardial infarction, unstable angina, late revascularization). Results: The registry included scans from 45,252 patients from 13 centers (55.9% male, 64.7 ± 11.8 y). Correlating invasive coronary angiography was available for 3,786 (8.4%) patients. CT attenuation correction imaging was available for 13,405 patients. MACEs occurred in 6,514 (14.4%) patients during a median follow-up of 3.6 y (interquartile range, 2.5–4.8 y). Patients with a stress total perfusion deficit of 5% to less than 10% (unadjusted hazard ratio [HR], 2.42; 95% CI, 2.23–2.62) and a stress total perfusion deficit of at least 10% (unadjusted HR, 3.85; 95% CI, 3.56–4.16) were more likely to experience MACEs. Patients with a deep learning CAC score of 101–400 (unadjusted HR, 3.09; 95% CI, 2.57–3.72) and a CAC of more than 400 (unadjusted HR, 5.17; 95% CI, 4.41–6.05) were at increased risk of MACEs. Conclusion: The REFINE SPECT registry contains a comprehensive set of imaging and clinical variables. It will aid in understanding the value of SPECT myocardial perfusion imaging, leverage hybrid imaging, and facilitate validation of new artificial intelligence tools for improving prediction of adverse outcomes incorporating multimodality imaging.




pd

Ependymal Tumors: Overview of the Recent World Health Organization Histopathologic and Genetic Updates with an Imaging Characteristic [CLINICAL PRACTICE]

SUMMARY:

The 2021 World Health Organization Classification of Tumors of the Central Nervous System (CNS5), introduced significant changes, impacting tumors ranging from glial to ependymal neoplasms. Ependymal tumors were previously classified and graded based on histopathology, which had limited clinical and prognostic utility. The updated CNS5 classification now divides ependymomas into 10 subgroups based on anatomic location (supratentorial, posterior fossa, and spinal compartment) and genomic markers. Supratentorial tumors are defined by zinc finger translocation associated (ZFTA) (formerly v-rel avian reticuloendotheliosis viral oncogene [RELA]), or yes-associated protein 1 (YAP1) fusion; posterior fossa tumors are classified into groups A (PFA) and B (PFB), spinal ependymomas are defined by MYCN amplification. Subependymomas are present across all these anatomic compartments. The new classification kept an open category of "not elsewhere classified" or "not otherwise specified" if no pathogenic gene fusion is identified or if the molecular diagnosis is not feasible. Although there is significant overlap in the imaging findings of these tumors, a neuroradiologist needs to be familiar with updated CNS5 classification to understand tumor behavior, for example, the higher tendency for tumor recurrence along the dural flap for ZFTA fusion-positive ependymomas. On imaging, supratentorial ZFTA-fused ependymomas are preferentially located in the cerebral cortex, carrying predominant cystic components. YAP1-MAMLD1-fused ependymomas are intra- or periventricular with prominent multinodular solid components and have significantly better prognosis than ZFTA-fused counterparts. PFA ependymomas are aggressive paramedian masses with frequent calcification, seen in young children, originating from the lateral part of the fourth ventricular roof. PFB ependymomas are usually midline, noncalcified solid-cystic masses seen in adolescents and young adults arising from the fourth ventricular floor. PFA has a poorer prognosis, higher recurrence, and higher metastatic rate than PFB. Myxopapillary spinal ependymomas are now considered grade II due to high recurrence rates. Spinal-MYCN ependymomas are aggressive tumors with frequent leptomeningeal spread, relapse, and poor prognosis. Subependymomas are noninvasive, intraventricular, slow-growing benign tumors with an excellent prognosis. Currently, the molecular classification does not enhance the clinicopathologic understanding of subependymoma and myxopapillary categories. However, given the molecular advancements, this will likely change in the future. This review provides an updated molecular classification of ependymoma, discusses the individual imaging characteristics, and briefly outlines the latest targeted molecular therapies.




pd

Academic Neuroradiology: 2023 Update on Turnaround Time, Financial Recruitment, and Retention Strategies [CLINICAL PRACTICE]

SUMMARY:

The ASNR Neuroradiology Division Chief Working Group's 2023 survey, with responses from 62 division chiefs, provides insights into turnaround times, faculty recruitment, moonlighting opportunities, and academic funds. In emergency cases, 61% aim for a turnaround time of less than 45–60 minutes, with two-thirds meeting this expectation more than 75% of the time. For inpatient CT and MR imaging scans, 54% achieve a turnaround time of 4–8 hours, with three-quarters meeting this expectation at least 50% of the time. Outpatient scans have an expected turnaround time of 24–48 hours, which is met in 50% of cases. Faculty recruitment strategies included 35% offering sign-on bonuses, with a median of $30,000. Additionally, 23% provided bonuses to fellows during fellowship to retain them in the practice upon completion of their fellowship. Internal moonlighting opportunities for faculty were offered by 70% of divisions, with a median pay of $250 per hour. The median annual academic fund for a full-time neuroradiology faculty member was $6000, typically excluding license fees but including American College of Radiology and American Board of Radiology membership, leaving $4000 for professional expenses. This survey calls for further dialogue on adapting and innovating academic institutions to meet evolving needs in neuroradiology.




pd

PD-L1+ diffuse large B-cell lymphoma with extremely high mutational burden and microsatellite instability due to acquired PMS2 mutation [RESEARCH REPORT]

We present a unique case of a single patient presenting with two mutationally distinct, PD-L1+ diffuse large B-cell lymphomas (DLBCLs). One of these DLBCLs demonstrated exceptionally high mutational burden (eight disease-associated variants and 41 variants of undetermined significance) with microsatellite instability (MSI) and an acquired PMS2 mutation with loss of PMS2 protein expression, detected postchemotherapy. This report, while highlighting the extent of possible tumor heterogeneity across separate clonal expansions as well as possible syndromic B-cell neoplasia, supports the notion that, although rare, PD-L1 expression and associated states permissive of high mutational burden (such as mismatch repair gene loss of function/MSI) should be more routinely considered in DLBCLs. Appropriate testing may be predictive of outcome and inform the utility of targeted therapy in these genetically diverse and historically treatment-refractory malignancies.




pd

Novel pathogenic PDX1 gene variant in a Korean family with maturity-onset diabetes of the young [VARIANT DISCREPANCY RESOLUTION]

The diagnosis of maturity-onset diabetes of the young (MODY), a monogenic form of diabetes mellitus caused by a mutation in a single gene, is often uncertain until genetic testing is performed. We report a 13-yr-old Korean boy who was initially diagnosed with type 2 diabetes (T2DM). MODY was suspected because of his nonobese body habitus and family history of multiple affected members. Targeted panel sequencing of all MODY-related genes was performed using the NextSeq 550Dx platform (Illumina). Sanger sequencing was performed using blood samples from the parents, siblings, and other relatives. A frameshift variant in the 3' region of the last exon of PDX1 was detected in the patient and his family members with diabetes. PP1_Moderate criterion was applied and this variant was confirmed to be the genetic cause of diabetes in the family and classified as likely pathogenic. The study highlights the importance of genetic testing for nonobese, early-onset diabetic patients with multiple affected family members. Increased awareness and aggressive genetic testing for MODY are needed.




pd

Cardiovascular disease &#x2014; risk assessment and reduction: NICE 2023 update for GPs




pd

New Tools Take Whole-Person Approach to Obesity Care [Family Medicine Updates]




pd

PBRNs: Past, Present, and Future: A NAPCRG Report on the Practice-Based Research Network Conference. [Family Medicine Updates]




pd

Impact of Health Equity Fellowships [Family Medicine Updates]




pd

The Changing Role of a Chair and DA: Follow-Up from the 2023 ADFM Annual Conference Session [Family Medicine Updates]




pd

Guidance and Resources for Family Medicine Scholarship [Family Medicine Updates]




pd

Management of opioid use disorder: 2024 update to the national clinical practice guideline [Guideline]

Background

In an evolving landscape of practices and policies, reviewing and incorporating the latest scientific evidence is necessary to ensure optimal clinical management for people with opioid use disorder. We provide a synopsis of the 2024 update of the 2018 National Guideline for the Clinical Management of Opioid Use Disorder, from the Canadian Research Initiative in Substance Matters.

Methods

For this update, we followed the United States Institute of Medicine’s Standards for Developing Trustworthy Clinical Practice Guidelines and used the Appraisal of Guidelines Research and Evaluation—Recommendation Excellence tool to ensure guideline quality. We carried out a comprehensive systematic literature review, capturing the relevant literature from Jan. 1, 2017, to Sept. 14, 2023. We drafted and graded recommendations according to the Grading of Recommendations, Assessments, Development and Evaluation approach. A multidisciplinary external national committee, which included people with living or lived experience of opioid use disorder, provided input that was incorporated into the guideline.

Recommendations

From the initial 11 recommendations in the 2018 guideline, 3 remained unchanged, and 8 were updated. Specifically, 4 recommendations were consolidated into a single revised recommendation; 1 recommendation was split into 2; another recommendation was moved to become a special consideration; and 2 recommendations were revised. Key changes have arisen from substantial evidence supporting that methadone and buprenorphine are similarly effective, particularly in reducing opioid use and adverse events, and both are now considered preferred first-line treatment options. Slow-release oral morphine is recommended as a second-line option. Psychosocial interventions can be offered as adjunctive treatment but should not be mandatory. The guideline reaffirms the importance of avoiding withdrawal management as a standalone intervention and of incorporating evidence-based harm reduction services along the continuum of care.

Interpretation

This guideline update presents new recommendations based on the latest literature for standardized management of opioid use disorder. The aim is to establish a robust foundation upon which provincial and territorial bodies can develop guidance for optimal care.




pd

Type 2 inflammation in COPD: is it just asthma?

COPD is a heterogeneous condition, with tobacco smoking being the main environmental risk factor. The presence of type 2 (T2) inflammation is a well-recognised feature of asthma; however, it is now apparent that a subset of COPD patients also displays evidence of T2 inflammation with respect to elevated eosinophil counts and altered gene and protein expression of several T2 inflammatory mediators. T2 inflammatory mediators represent an attractive therapeutic target in both COPD and asthma; however, the efficacy of pharmaceutical interventions varies between diseases. Furthermore, the nature of some shared clinical features also differs. We provide a narrative review of differences in the nature of T2 inflammation between COPD and asthma, which may partly explain phenotypic differences between diseases. We focus on evidence from studies of pulmonary histopathology, sputum and epithelial gene and protein expression, and response to pharmacological interventions targeted at T2 inflammation.




pd

Capcom Updates Its Best-Sellers List - Monster Hunter World at 20.9M, RE4 Remake at 8M, More

Capcom has updated its list of Platinum Titles, games that have sold over one million units as of September 30, 2024. The list includes 122 games with sales over one million units, 64 over two million units, 14 over five million units, and six over 10 million units sold.

Resident Evil 4 remake sold 400,000 units to bring lifetime sales to eight million units, Resident Evil 2 remake sold 300,000 units to bring sales to 14.5 million units, and Resident Evil 3 remake sold 200,000 units to bring lifetime sales to 9.2 million units. 

Resident Evil 7: biohazard sold 300,000 units to bring lifetime sales to 14 million units and Resident Evil Village sold 400,000 units to bring sales to 10.5 million units.

Monster Hunter Rise sold 600,000 units in the quarter to bring lifetime sales to 16 million units. Monster Hunter Rise: Sunbreak sold 400,000 units to bring lifetime sales to 8.8 million units.

Monster Hunter: World sold 400,000 units in the quarter to bring lifetime sales to 20.9 million units, while the Iceborne expansion sold 600,000 units for a total of 14 million units.

Dragon's Dogma 2 sold 300,000 units in the quarter to bring lifetime sales to 3.3 million units. Street Fighter 6 sold 400,000 units in the quarter to bring lifetime sales to 4.1 million units. Devil May Cry 5 sold 300,000 units to bring sales to 8.7 million units. 

Check out the complete list below:

Release Title Platform Million
units
1 Jan 2018 Monster Hunter: World

*Unit sales including Monster Hunter World: Iceborne Master Edition: 27.00 million units

PS4, Xbox One, PC, DL 20.90*
2 Mar 2021 Monster Hunter Rise NSW, PS4, PS5, Xbox One, XSX, PC, DL 16.00
3 Jan 2019 Resident Evil 2 PS4, PS5, Xbox One, XSX, NSW, PC, DL 14.50
4 Jan 2017 RESIDENT EVIL 7 biohazard PS4, PS5, Xbox One, XSX, NSW, PC, DL 14.00
5 Sep 2019 Monster Hunter World: Iceborne PS4, Xbox One, PC, DL 14.00
6 May 2021 Resident Evil Village PS4, PS5, Xbox One, XSX, NSW, PC, DL 10.50
7 Mar 2009 Resident Evil 5 PS3, Xbox 360, DL 9.40
8 Oct 2012 Resident Evil 6 PS3, Xbox 360, DL 9.30
9 Apr 2020 Resident Evil 3 PS4, PS5, Xbox One, XSX, NSW, PC, DL 9.20
10 Jun 2022 Monster Hunter Rise: Sunbreak NSW, PS4, PS5, Xbox One, XSX, PC, DL 8.80
11 Mar 2019 Devil May Cry 5 PS4, Xbox One, PC, DL 8.70
12 Mar 2023 Resident Evil 4 PS4, PS5, XSX, PC, DL 8.00
13 Feb 2016 Street Fighter V PS4、PC、DL 7.70
14 Jun 1992 Street Fighter II SNES 6.30
15 Jan 1998 Resident Evil 2 PS 4.96
16 Dec 2010 Monster Hunter Freedom 3 PSP, DL 4.90
17 Mar 2017 Monster Hunter Generations Ultimate 3DS, NSW, DL 4.90
18 Nov 2014 Resident Evil PS3, DL 4.50
19 Jan 2016 Resident Evil 0: HD Remaster PS3, PS4, Xbox One, PC, DL 4.40
20 Nov 2015 Monster Hunter Generations 3DS, DL 4.30
21 Oct 2014 Monster Hunter 4 Ultimate 3DS, DL 4.20
22 Jun 2023 Street Fighter 6 PS4, PS5, XSX, PC, DL 4.10
23 Sep 2013 Monster Hunter 4 3DS, DL 4.10
24 Jul 1993 Street Fighter II Turbo SNES 4.10
25 Apr 2013 Dragon’s Dogma: Dark Arisen PS3, Xbox 360, DL 4.00
26 Mar 2008 Monster Hunter Freedom Unite PSP, DL 3.80
27 Feb 2019 Phoenix Wright: Ace Attorney Trilogy PS4, NSW, DL 3.80
28 Nov 2013 Dead Rising 3 Xbox One, DL 3.80
29 Feb 2009 Street Fighter IV PS3, Xbox 360, DL 3.60
30 Mar 2015 Resident Evil Revelations 2 PS3, PS4, Xbox 360, Xbox One, PC, DL 3.60
31 Mar 2016 Resident Evil 6 PS4, Xbox One, DL 3.50
32 Sep 1999 Resident Evil 3 Nemesis PS 3.50
33 May 2018 Street Fighter 30th Anniversary Collection PS4, Xbox One, NSW, PC, DL 3.40
34 Jun 2016 Resident Evil 5 PS4, Xbox One, DL 3.30
35 Aug 2016 Resident Evil 4 PS4, Xbox One, DL 3.30
36 Mar 2024 Dragon’s Dogma 2 PS5, XSX, DL 3.30
37 Sep 2010 Dead Rising 2 PS3, Xbox 360, PC, DL 3.20
38 Jan 2013 DmC Devil May Cry PS3, Xbox 360, DL 3.10
39 Jan 2008 Devil May Cry 4 PS3, Xbox 360, DL 3.00
40 Feb 2014 Resident Evil 4: Ultimate HD Edition PC, DL 3.00
41 Jun 2015 Devil May Cry 4 Special Edition PS4, Xbox One, DL 2.80
42 Mar 1996 Resident Evil PS 2.75
43 May 2013 Resident Evil Revelations PS3, Xbox 360, Wii U, PC, DL 2.70
44 Mar 2012 Resident Evil: Operation Raccoon City PS3, Xbox 360, DL 2.70
45 Dec 2011 Monster Hunter 3 Ultimate 3DS, DL 2.60
46 Oct 2017 Dragon’s Dogma: Dark Arisen PS4, Xbox One, DL 2.50
47 Dec 2017 Okami HD PS4, Xbox One, NSW, DL 2.50
48 Feb 2021 Capcom Arcade Stadium DL (PS4, Xbox One, NSW, PC) 2.40
49 Feb 2007 Monster Hunter Freedom 2 PSP 2.40
50 Feb 2010 Resident Evil 5: Gold Edition PS3, Xbox 360, DL 2.40
51 Jul 1999 Dino Crisis PS 2.40
52 Sep 2017 Marvel vs. Capcom: Infinite PS4, Xbox One, PC, DL 2.30
53 Dec 2005 Resident Evil 4 PS2 2.30
54 Aug 2014 Ultra Street Fighter IV PS3, Xbox 360, PC, DL 2.20
55 Feb 2011 Marvel vs. Capcom 3: Fate of Two Worlds PS3, Xbox 360 2.20
56 May 2010 Lost Planet 2 PS3, Xbox 360, DL 2.20
57 Aug 2001 Devil May Cry PS2 2.16
58 Mar 2002 Onimusha 2: Samurai’s Destiny PS2 2.10
59 Jan 2001 Onimusha: Warlords PS2 2.02
60 Jul 2021 Monster Hunter Stories 2: Wings of Ruin NSW, PS4, PC, DL 2.00
61 Mar 2017 Ultimate Marvel vs. Capcom 3 PS4, Xbox One, DL 2.00
62 May 2007 Resident Evil 4 Wii edition Wii, DL 2.00
63 Mar 2018 Devil May Cry HD Collection PS4, Xbox One, DL 2.00
64 Jun 1994 Super Street Fighter II SNES 2.00
65 Aug 2009 Monster Hunter Tri Wii 1.90
66 Oct 2018 Mega Man 11 PS4, Xbox One, NSW, DL 1.90
67 Apr 2010 Super Street Fighter IV PS3, Xbox 360, DL 1.90
68 Mar 2012 Street Fighter X Tekken PS3, Xbox 360, DL 1.90
69 Aug 2006 Dead Rising Xbox 360, DL 1.80
70 Jul 2022 Capcom Arcade 2nd Stadium DL (PS4, Xbox One, NSW, PC) 1.80
71 Dec 2006 Lost Planet Extreme Condition Xbox 360, DL 1.70
72 Nov 2013 DuckTales: Remastered PS3, Xbox 360, Wii U, DL 1.70
73 Jan 2003 Devil May Cry 2 PS2 1.70
74 Sep 1993 Street Fighter II’ Special Champion Edition MD 1.65
75 Jun 1986 Ghosts’n Goblins NES 1.64
76 Aug 2015 Mega Man Legacy Collection PS4, Xbox One, DL 1.60
77 Dec 2016 Dead Rising 4 Xbox One, PC, DL 1.60
78 Jan 2005 Resident Evil 4 GC 1.60
79 Feb 2004 Onimusha 3: Demon Siege PS2 1.52
80 Dec 1988 Mega Man 2 NES 1.51
81 Sep 2016 Dead Rising PS4, Xbox One, DL 1.50
82 Jun 2013 Remember Me PS3, Xbox 360, PC, DL 1.50
83 Nov 2017 Resident Evil Revelations Collection NSW, DL 1.50
84 Feb 2014 Strider DL(PS3, PS4, Xbox 360, Xbox One, PC) 1.50
85 Oct 2010 Dead Rising 2 Off The Record PS3, Xbox 360, DL 1.50
86 Dec 1990 Final Fight SNES 1.48
87 Dec 2003 Resident Evil Outbreak PS2 1.45
88 Mar 2001 Resident Evil Code: Veronica X PS2, DC 1.40
89 Jul 2009 Marvel vs. Capcom 2: New Age Of Heroes DL (PS3, Xbox 360) 1.40
90 Sep 2014 Dead Rising 3 Apocalypse Edition PC, DL 1.40
91 Mar 2015 DmC Devil May Cry Definitive Edition PS4, Xbox One, DL 1.40
92 Mar 2002 Resident Evil GC 1.35
93 Dec 2003 Mega Man Battle Network 4 GBA 1.35
94 Jul 2018 Mega Man X Legacy Collection PS4, Xbox One, NSW, DL 1.30
95 Jun 2009 Bionic Commando PS3, Xbox 360, PC, DL 1.30
96 May 2012 Dragon’s Dogma PS3, Xbox 360 1.30
97 Feb 2011 Super Street Fighter IV 3D Edition 3DS, DL 1.30
98 Dec 2005 Monster Hunter Freedom PSP, DL 1.30
99 Mar 2012 Resident Evil 4 DL(PS3, Xbox 360) 1.30
100 Nov 2007 Resident Evil: The Umbrella Chronicles Wii 1.30
101 Feb 2005 Devil May Cry 3 PS2 1.30
102 Nov 2002 Resident Evil 0 GC 1.25
103 Jun 2011 Super Street Fighter IV Arcade Edition PS3, Xbox 360, DL 1.20
104 Sep 2000 Dino Crisis 2 PS 1.20
105 Nov 2011 Ultimate Marvel vs. Capcom 3 PS3, Xbox 360, DL 1.20
106 Mar 2012 Devil May Cry HD Collection PS3, Xbox 360, DL 1.20
107 Apr 2019 Dragon’s Dogma DARK ARISEN NSW, DL 1.20
108 Sep 2016 Dead Rising 2 Off The Record PS4, Xbox One, DL 1.20
109 Aug 1998 Resident Evil Director’s Cut Dual Shock PS 1.20
110 Dec 1993 Mega Man X SNES 1.16
111 Feb 2000 Resident Evil Code: Veronica DC 1.14
112 Sep 1986 Commando NES 1.14
113 Sep 1997 Resident Evil Director’s Cut PS 1.13
114 Aug 2017 Resident Evil Revelations PS4, Xbox One, DL 1.10
115 Jul 2021 The Great Ace Attorney Chronicles PS4, NSW, DL 1.10
116 Oct 1991 Super Ghouls’n Ghosts SNES 1.09
117 Sep 1990 Mega Man 3 NES 1.08
118 May 1993 Final Fight 2 SNES 1.03
119 Oct 2019 Resident Evil 6 DL (NSW) 1.00
120 Dec 1998 Street Fighter Alpha 3 PS 1.00
121 Jul 2018 Megaman X Anniversary Collection 2 PS4, Xbox One, NSW, DL 1.00
122 Feb 2006 Devil May Cry 3 Special Edition PS2 1.00

A life-long and avid gamer, William D'Angelo was first introduced to VGChartz in 2007. After years of supporting the site, he was brought on in 2010 as a junior analyst, working his way up to lead analyst in 2012 and taking over the hardware estimates in 2017. He has expanded his involvement in the gaming community by producing content on his own YouTube channel and Twitch channel. You can contact the author on Twitter @TrunksWD.

Full Article - https://www.vgchartz.com/article/463020/capcom-updates-its-best-sellers-list-monster-hunter-world-at-209m-re4-remake-at-8m-more/